The microculture-kinetic (MiCK) assay: The role of a drug-induced apoptosis assay in drug development and clinical care Journal Article
| Authors: | Bosserman, L.; Prendergast, F.; Herbst, R.; Fleisher, M.; Salom, E.; Strickland, S.; Raptis, A.; Hallquist, A.; Perree, M.; Rajurkar, S.; Karimi, M.; Rogers, K.; Davidson, D.; Willis, C.; Penalver, M.; Homesley, H.; Burrell, M.; Garrett, A.; Rutledge, J.; Chernick, M.; Presant, C. A. |
| Article Title: | The microculture-kinetic (MiCK) assay: The role of a drug-induced apoptosis assay in drug development and clinical care |
| Abstract: | A drug-induced apoptosis assay, termed the microculture-kinetic (MiCK) assay, has been developed. Blinded clinical trials have shown higher response rates and longer survival in groups of patients with acute myelocytic leukemia and epithelial ovarian cancer who have been treated with drugs that show high apoptosis in the MiCK assay. Unblinded clinical trials in multiple tumor types have shown that the assay will be used frequently by clinicians to determine treatment, and when used, results in higher response rates, longer times to relapse, and longer survivals. Model economic analyses suggest possible cost savings in clinical use based on increased generic drug use and single-agent substitution for combination therapies. Two initial studies with drugs in development are promising. The assay may help reduce costs and speed time to drug approval. Correlative studies with molecular biomarkers are planned. This assay may have a role both in personalized clinical therapy and in more efficient drug development. ©2012 AACR. |
| Keywords: | treatment response; leukemia; acute granulocytic leukemia; overall survival; review; doxorubicin; fluorouracil; cancer combination chemotherapy; treatment duration; antineoplastic agents; drug approval; capecitabine; gemcitabine; paclitaxel; cytarabine; methotrexate; outcome assessment; antineoplastic agent; neoplasms; colorectal cancer; medical decision making; biological marker; apoptosis; breast cancer; analytic method; cyclophosphamide; antineoplastic activity; cancer cell culture; drug resistance; drug screening assays, antitumor; drug discovery; cell line, tumor; docetaxel; irinotecan; chronic disease; cost control; health care cost; survival time; drug research; folinic acid; daunorubicin; ovary carcinoma; cancer relapse; epirubicin; idarubicin; cancer classification; anthracycline; oxaliplatin; drug sensitivity; pemetrexed; optical density; concentration response; drug use; correlational study; personalized medicine; drug choice; clinical trial (topic); incubation time; hl-60 cells; cancer prognosis; microculture kinetic assay |
| Journal Title: | Cancer Research |
| Volume: | 72 |
| Issue: | 16 |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2012-08-15 |
| Start Page: | 3901 |
| End Page: | 3905 |
| Language: | English |
| DOI: | 10.1158/0008-5472.can-12-0681 |
| PROVIDER: | scopus |
| PUBMED: | 22865459 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 4 September 2012" - "CODEN: CNREA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work